400-885-9898
更新于 1月16日
智聯(lián)APPAPP
舉報

財務BP-生產(chǎn)方向(J16389)

2.6萬-4萬·16薪
  • 上海徐匯區(qū)
  • 5-10年
  • 本科
  • 全職
  • 招1人

職位描述

生產(chǎn)財務BP
崗位職責:
1.As Production/Quality/Engineering/supporting/CDMO/CRO team business partner, support their daily operation in finance area, including but not limited in policy guidance, compliance, business process improvement, business growth suggestion, cost reduction.
2.Actual performance analysis and reporting including cost center spending analysis, product cost variance analysis, inventory analysis, CAPEX investment analysis, HC utilization, equipment utilization, and other required analysis.
3.Cost estimation simulation for business changes and decisions.
4.Annual budget and regular forecast
5.Budget control and cost reduction with the team to continuously improve product cost structure, MRP, purchasing, inventory and other related area.
6.Supporting purchasing price negotiation with vendor, to achieve the corporate continuous cost reduction.
7.Tracking CAPEX investment and control spending speed.
8.Co-ordination and support with other finance BPs and functions.
9.Lead or attend digital transformation projects like SAP,BI.
10.Other tasks required by supported teams and the company.

任職要求:
1. Bachelor degree, major in accounting or related.
2. Over 8 years working experience and over 3 years overall manufacture BP/controller expense is must.
3. Bio pharmacy production plant experience is preferred.
4. Work independently, can work under pressure and result driven
5. Smart, fast learning and with highly EQ
6. Coordination, willing to team working and growth together with team
7. Flexibility, willing to take the challenge from various function.

工作地點

華鑫慧享城B區(qū)8棟11樓

職位發(fā)布者

鄒女士/HR

立即溝通
公司Logo上海復宏漢霖生物技術股份有限公司
復宏漢霖（2696.HK）是一家國際化的創(chuàng)新生物制藥公司，致力于為全球患者提供可負擔的高品質(zhì)生物藥，產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領域，已在中國上市5款產(chǎn)品，在國際上市1款產(chǎn)品，18項適應癥獲批，3個上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來，復宏漢霖已建成一體化生物制藥平臺，高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心，按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）標準進行生產(chǎn)和質(zhì)量管控，不斷夯實一體化綜合生產(chǎn)平臺，其中，上海徐匯基地已獲得中國和歐盟GMP認證，松江基地（一）也已獲得中國GMP認證。復宏漢霖前瞻性布局了一個多元化、高質(zhì)量的產(chǎn)品管線，涵蓋20多種創(chuàng)新單克隆抗體，并全面推進基于自有抗PD-1單抗H藥漢斯狀?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個生物類似藥漢利康?（利妥昔單抗）、中國首個自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?（曲妥珠單抗，歐洲商品名：Zercepac?，澳大利亞商品名：Tuzucip?和Trastucip?）、漢達遠?（阿達木單抗）和漢貝泰?（貝伐珠單抗）相繼獲批上市，創(chuàng)新產(chǎn)品漢斯狀?（斯魯利單抗）已獲批用于治療微衛(wèi)星高度不穩(wěn)定（MSI-H）實體瘤、鱗狀非小細胞肺癌和廣泛期小細胞肺癌，成為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗，其食管鱗狀細胞癌適應癥的上市注冊申請也正在審評中。公司亦同步就16個產(chǎn)品在全球范圍內(nèi)開展30多項臨床試驗。
公司主頁